rethinkTHC Search
Menu
Study breakdown

COX-2 creates inflammatory molecules from endocannabinoids, not just destroys them

ReviewPreliminary evidence
The takeaway

When the inflammatory enzyme COX-2 breaks down endocannabinoids, it does not just eliminate them but creates entirely new bioactive molecules that may play their own roles in inflammation.

Read this if you want to understand the hidden connection between anti-inflammatory drugs and the endocannabinoid system.

COX-2 converts endocannabinoids into novel bioactive inflammatory molecules

What the researchers found

This review explored a lesser-known function of COX-2, an enzyme best known for producing prostaglandins during inflammation. COX-2 also metabolizes the two main endocannabinoids, anandamide (AEA) and 2-AG. Rather than simply inactivating these endocannabinoids, COX-2 converts them into prostaglandin analogs: PG-glycerol esters from 2-AG and prostamides from AEA.

These COX-2-derived endocannabinoid metabolites are distinct from classical prostaglandins and appear to have their own biological effects, particularly in inflammation. The review synthesized emerging in vivo evidence about the roles of these novel lipid mediators.

Why it matters

NSAIDs and other COX-2 inhibitors are among the most widely used medications. Understanding that COX-2 generates bioactive metabolites from endocannabinoids adds complexity to how we understand both anti-inflammatory drug effects and endocannabinoid system function.

The numbers in context

Two endocannabinoids (AEA and 2-AG) are metabolized by COX-2 into two classes of products (prostamides and PG-glycerol esters). The biological significance of these metabolites was still being characterized at the time of publication.

How the study worked

Narrative review of published literature on COX-2 metabolism of endocannabinoids, the generation of prostaglandin-glycerol esters and prostamides, and their biological effects in inflammatory processes.

What this study cannot tell us

The biological effects of these COX-2-derived endocannabinoid metabolites were not fully characterized at the time of publication. Much of the evidence came from in vitro and animal studies. The clinical relevance for human inflammation remained to be established.

How to read the evidence

Narrative review synthesizing emerging preclinical evidence. The biological significance of these metabolites was still being established.

When this study was published

Published in 2014. Research on endocannabinoid-derived prostanoids has continued to develop.

The bigger picture

This review highlighted an intersection between the prostaglandin and endocannabinoid systems that is often overlooked. When COX-2 is blocked by anti-inflammatory drugs, the downstream effects include not just reduced prostaglandins but also altered endocannabinoid metabolism, which may contribute to the therapeutic or side effects of these common medications.

Questions still open

  • Do COX-2-derived endocannabinoid metabolites contribute to the anti-inflammatory effects of NSAIDs? Could targeting these specific metabolic pathways offer more precise anti-inflammatory treatments? How do these metabolites interact with cannabinoid receptors?

Common questions

What happens when COX-2 breaks down endocannabinoids?
Instead of simply inactivating them, COX-2 converts endocannabinoids into prostaglandin analogs that have their own biological effects on inflammation. These are different from the classical prostaglandins made from arachidonic acid.
Does this affect how anti-inflammatory drugs work?
Potentially. When COX-2 inhibitors block this enzyme, they affect not only prostaglandin production but also endocannabinoid metabolism, which may contribute to the drugs' effects in ways not previously recognized.

Read the original research

COX-2-derived endocannabinoid metabolites as novel inflammatory mediators.

Trends in pharmacological sciences, 35(6), 284-92

Citation

Alhouayek, Mireille; Muccioli, Giulio G. (2014). COX-2-derived endocannabinoid metabolites as novel inflammatory mediators.. Trends in pharmacological sciences, 35(6), 284-92. https://doi.org/10.1016/j.tips.2014.03.001

Explore the wider topic